Hypothermic oxygenated perfusion (HOPE) safely and effectively extends acceptable donor heart preservation times: Results of the Australian and New Zealand trial
David C. McGiffin(The University of Queensland), David M. Kaye(Alfred Health), P. Jansz(Victor Chang Cardiac Research Institute), C. Cheshire(The Alfred Hospital), Atsuo Doi(The Alfred Hospital), James Hare(The Alfred Hospital), Amul Kumar Sibal(Auckland City Hospital), Christopher Merry(The Alfred Hospital), John F. Fraser(The University of Queensland), Silvana Marasco(The Alfred Hospital), Eldho Paul(Monash Health), Jacob Mathew(Royal Children's Hospital), A. Geldenhuys(Fiona Stanley Hospital), Peter S. Macdonald(St Vincent's Hospital Sydney), Christina Kure(The Alfred Hospital), Cara A. Wasywich(Auckland City Hospital), Angeline Leet(The Alfred Hospital), Robert Larbalestier(Fiona Stanley Hospital), S. Emmanuel(St Vincent's Hospital Melbourne), Sandra E. Graham(The Alfred Hospital), Amit Shah(Fiona Stanley Hospital)
Cited by 89
Related Papers
Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry
|The Lancet|2020|945
Adverse consequences of high sympathetic nervous activity in the failing human heart
|Journal of the American College of Cardiology|1995|665
Position Paper for the Organization of Extracorporeal Membrane Oxygenation Programs for Acute Respiratory Failure in Adult Patients
|American Journal of Respiratory and Critical Care Medicine|2014|518
Sympathetic Augmentation in Hypertension
|Hypertension|2003|512
Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease
|Science Translational Medicine|2015|496